Society for Translational Oncology Announces 2011 Chabner Colloquium: Collaboration in Cancer Drug Trials

Share Article

The Society for Translational Oncology (STO) is pleased to announce online registration is available for the 2011 Chabner Colloquium: Collaboration in Cancer Drug Trials which will take place on October 24-25, 2011 at Norton’s Woods Conference Center, in Cambridge, Massachusetts. This continuing medical education (CME) symposium is jointly sponsored by The Massachusetts General Hospital Cancer Center and STO in partnership with STO’s official journal, The Oncologist.

The Society for Translational Oncology (STO) is pleased to announce online registration is available for the 2011 Chabner Colloquium: Collaboration in Cancer Drug Trials which will take place on October 24-25, 2011 at Norton’s Woods Conference Center, in Cambridge, Massachusetts. This continuing medical education (CME) symposium is jointly sponsored by The Massachusetts General Hospital Cancer Center and STO in partnership with STO’s official journal, The Oncologist.

Registration for the 2011 Chabner Colloquium is available online: https://theoncologistcommunity.com/registration/

The symposium will feature keynote lectures from renowned physician scientists. On Monday, October 24, Dr. Daniel Haber will lecture on molecular analysis of very rare circulating tumor cells (CTC’s). Dr. Haber's research has shown that the change in the amount of CTCs in the blood correlates well with treatment effectiveness. Dr. Haber is the Director of The Massachusetts General Hospital Cancer Center and the Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology at Harvard Medical School, Boston, Massachusetts.

On Tuesday, October 25, Dr. James Doroshow will speak about targeted drug development from the perspective of the National Cancer Institute (NCI). Dr Doroshow has been the Director of Division of Cancer Treatment and Diagnosis at the NCI since 2004, and is currently Deputy Director for Clinical and Translational Research, NCI. In addition, he is Senior Investigator and Head, Oxidative Signaling and Molecular Therapeutics Section at the Center for Cancer Research, NCI, in Bethesda, Maryland.

Also on Tuesday, October 25, Dr. David Schenkein will lecture on metabolomics as a target. Dr Schenkein is CEO of Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism.
This unique conference was first held in November 2010 and attended by over 140 scientists, clinical investigators and industry researchers. It offered an intimate look at some of the best biomedical research ongoing in Boston and regional hospitals and universities, and in local biotechs and industry. Speakers covered a range of topics, from clinical trials to basic concepts in RNA function, but they shared one common characteristic: all were at the forefront of an exciting field of research. “The talks were remarkable; often spell binding, and in some cases presaging the publication of paradigm changing work. The audience uniformly praised the meeting as the best of its kind, a small and highly interactive gathering with top quality science and clinical investigation side by side with perspectives from both academia and industry. I look forward to insightful discussions this year,” said Dr. Bruce A. Chabner, Director of Clinical Research, Massachusetts General Hospital Cancer Center and Professor of Medicine, Harvard Medical School. Dr Chabner is Editor-in-Chief of The Oncologist and chairman of the 2011 Chabner Colloquium which bears his name.

STO is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This day and a half symposium will be designated for a maximum of 11 AMA PRA Category 1 Credit(s)™ .
Online registration site: https://theoncologistcommunity.com/registration/
For more information, contact STO at (919) 433-0489 or via e-mail to admin(at)sto-online(dot)org.

About the Society for Translational Oncology
STO is a non-profit, tax exempt association whose mission is to speed the discovery and translation of important new treatments in the field of cancer medicine to the practice of global oncology. STO brings knowledge and strategies for critical new developments in cancer treatment to the practice of the community oncologist. For more information, visit: http://www.sto-online.org.

About The Oncologist
Recognized as a premier peer-reviewed cancer medicine journal, The Oncologist, now in its sixteenth year, is devoted to physicians entrusted with the care of cancer patients. The Oncologist is the official publication of the Society for Translational Oncology. For more information, visit: http://www.theoncologist.com.
About The Massachusetts General Hospital Cancer Center
A Comprehensive Cancer Center

An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.

U.S. News & World Report consistently ranks the Mass General Cancer Center as one of the top ten cancer centers in the country. Its nurses were the first in Massachusetts to achieve Magnet status from the American Nurses Credentialing Center in recognition of the hospital's exceptional nursing care.

Known for providing customized, innovative treatments and compassionate care to both adults and children, the Cancer Center comprises 23 fully integrated, multidisciplinary clinical programs and a vast array of support and educational services. Its network of affiliations extends throughout New England and the southeastern U.S.

The Cancer Center’s commitment to eradicating cancer is fueled by scientific investigation conducted as part of one of the largest hospital-based research programs in the nation. Through a powerful synergy between laboratory scientists and bedside physicians, the Mass General Cancer Center fosters innovation in all phases of cancer research. Physician investigators conduct nearly 400 clinical trials annually.

The Massachusetts General Hospital Cancer Center is proud to be a founding member of a Harvard Medical School consortium designated by the National Cancer Institute as a comprehensive cancer center. This prestigious seven-member center forms the largest cancer research collaboration in the country. The promising new treatments developed through this partnership are revolutionizing the future of cancer medicine. For more information, visit: http://www.massgeneral.org/cancer/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gabby Cruze, CCMEP